© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Tolfenamic acid, a well-recognized nonsteroidal anti-inflammatory drug (NSAID), draws attention for its ability to manage pain and inflammation in both veterinary and human pharmaceutical applications. Its origins track back to exploration of fenamate derivatives, evolving into a core option used for migraines, musculoskeletal discomfort, and animal health. The compound takes on the IUPAC designation of 2-[(3-chloro-2-methylphenyl)amino]benzoic acid, consolidating its place among carboxylic acid-based analgesics. My own experiences working with molecules similar to tolfenamic acid underline how valuable a stable crystalline structure and robust physical profile are for formulation labs, where every property can determine the route of administration and the processing steps that follow.
Sourcing tolfenamic acid generally involves working with fine powders, crystalline solids, or, less commonly, liquid solutions. Many pharmaceutical firms and chemical suppliers package it in solid bulk, sometimes as yellowish-white crystals or white flakes that convey its purity. Dosing flexibility results from blending tolfenamic acid powder into tablets, oral suspensions, or veterinary injectables—particularly when controlling the rapid release required for acute pain. Raw material suppliers focus on traceability, ensuring each batch meets specification requirements set by pharmacopeias and health regulations. For industries, access to technical-grade and pharmaceutical-grade tolfenamic acid enables a wide reach from R&D to final-product manufacturing, important in efforts to maintain reliable supply and compliance with worldwide standards.
Chemically, tolfenamic acid’s structure features a benzoic acid backbone with a 3-chloro-2-methyl aniline moiety. Its molecular formula stands as C14H12ClNO2, with a molar mass of about 261.7 g/mol. Density clocks in around 1.34 g/cm³, a solid value that supports straightforward transport and storage. The crystalline nature helps with stability. Melting occurs close to 213°C, a high enough point for most production environments. Solubility tends to be limited in water but demonstrates greater dispersibility in organic solvents like dimethyl sulfoxide, methanol, or ethanol—a property that formulation chemists consider in drug design, especially when choosing carriers for poorly water-soluble actives. This low aqueous solubility, viewed as a technical hurdle, demands either micronization of the active ingredient to increase surface area or combination with surfactants and polymers to push bioavailability higher.
For exporters and customs authorities, tolfenamic acid usually falls under HS Code 291639. This category—encompassing other aromatic carboxylic acids and their derivatives—tracks shipments worldwide and affects duties or export regulations. Documentation covers purity claims, typically above 98%, and appearance, with some manufacturers describing free-flowing powders or defined solid flakes. Packing frequently uses fiber drums lined with polyethylene bags to guard against moisture ingress, light exposure, or contamination. Standard product specification sheets clarify melting point, refractive index in solution, residue on ignition, and heavy metal content, providing buyers a clear picture of compliance with ICH Q7 and Good Manufacturing Practice (GMP) standards.
Tolfenamic acid appears in commerce as crystalline solid, white to faint yellow, with a touch of luster visible in the flaky form. Handling characteristics—flowability, tendency to agglomerate, dustiness—affect processing, especially when blending with other tablet excipients. A high melting point not only secures product integrity but also reduces the risk of decomposition during high-heat processing. Particle morphology, as controlled through crystallization steps, influences how reliably the compound moves through feeders, mixers, and screeners in pharmaceutical plants. In some research labs, I’ve seen the challenge posed by material that clumps into pearls or cakes under improper humidity storage—reminding anyone sourcing tolfenamic acid that conditions must always be verified, especially for clinical applications.
Hazard evaluations emphasize that tolfenamic acid, though a beneficial NSAID, presents health risks when handled without protection. Inhalation or skin contact with powder traces can cause irritation, so standard operating procedures call for masks, gloves, and proper exhaust hoods. Material safety data sheets (MSDS) highlight concerns regarding environmental exposure, particularly if raw materials enter wastewater. For all chemicals, including tolfenamic acid, storage in cool, dry, well-ventilated conditions limits hazards from degradation products or accidental spillage. Industrial users rely on the globally harmonized system (GHS) to classify its risk profile—labeling it as harmful if swallowed and as a possible eye irritant. Waste management strategies, including recovery or controlled incineration, must satisfy both local and international regulations. In practice, adhering to REACH and OSHA standards builds trust between supplier and user, keeps the workforce safe, and protects the environment.
Tolfenamic acid production starts with precursor chemicals like o-toluidine and 3-chloroaniline, followed by acylation steps to form the core framework. As an experienced industry observer, I’ve seen that quality depends heavily on controlling residual solvents and trace impurities—factors which can make or break the downstream product quality for tablets or injectables. Lot-to-lot variability remains a risk when starting from different raw material suppliers, so in-house qualification processes, stringent third-party audits, and validation protocols all play a role. The best results come from transparent supply chains, routine analytical testing, and real-time feedback to ensure that specification sheet claims match delivered material reality. Collaboration among chemists, logistics managers, and auditors creates resilience against supply shocks, unplanned delays, or regulatory challenges.
Complexity around tolfenamic acid goes beyond chemistry, touching policy, ethics, and sustainable sourcing. As countries tighten controls on hazardous chemicals, industrial actors must document every step, from raw material origin to end-user delivery. Safe handling standards, coupled with transparent reporting, address public health concerns while advancing trust with regulatory agencies. At the same time, innovation drives the search for new tolfenamic acid formulations—better solubilizers, improved crystal habits, and eco-friendly synthetic approaches. Training and investment in modern analytical tools—like HPLC, mass spectrometry, and particle characterization—equip labs to meet new challenges and find better solutions for pain relief and anti-inflammatory needs. Each improvement, no matter how small, adds up to better patient outcomes and safer workplaces in a world that increasingly prizes chemical stewardship.
